May 03, 2016
Article
POLICY
Advances in treatment for hepatitis C virus (HCV) have the potential to generate considerable spillover benefits to patients awaiting transplants, especially among those with non—HCV-mediated liver failure.
May 03, 2016
Article
CLINICAL
The authors examine real-world hepatitis C virus cure rates with direct-acting antivirals among patients coinfected with HIV.
May 03, 2016
Article
POLICY
Expanding private-payer coverage of hepatitis C treatment may yield significant long-term cost savings for private payers, reduced costs to Medicare, and increased social value.
May 03, 2016
Article
POLICY
Expanding screening for hepatitis C virus infection may generate substantial benefits for patients and society, but only when paired with expanded treatment policies.
May 03, 2016
Article
FROM THE EDITORS
This special issue presents important new peer-reviewed research, covering issues ranging from access and the out-of-pocket costs of a treatment course, to the real-world consequences-both economic and clinical-of failing to treat.
May 03, 2016
Article
CLINICAL
Member cost negatively affects initial medication adherence and manufacturer coupons can decrease member share by up to 98%.
May 03, 2016
Article
CLINICAL
In the treatment of hepatitis C virus, the gap between efficacy and real-world effectiveness narrows with improved tolerability and ease of use.
May 03, 2016
Article
POLICY
This study analyzes the current coverage designs for hepatitis C virus drugs by Medicare Part D plans.
May 03, 2016
Article
COMMENTARY
Despite the high cost of novel hepatitis C treatments and patients' apparent willingness to bear part of it, high patient cost sharing is both inefficient and inequitable.